Avsola (infliximab-axxq) — FDA-Approved Biosimilar to Remicade (infliximab)

TNF-alpha Inhibitor Biosimilar (IV) · Approved 2019 · $0–$35/mo for most insured patients

🔬 What Is Avsola?

Avsola (infliximab-axxq) is an FDA-approved biosimilar to Remicade (infliximab). A biosimilar is a biological medication that is highly similar to an already-approved reference biologic, with no clinically meaningful differences in safety, purity, or potency. Avsola (infliximab-axxq) is an FDA-approved Remicade biosimilar from Amgen. It is given by intravenous (IV) infusion and approved for all Remicade indications including RA, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis.

🛒 Order Avsola — Direct from BiologicHealthPlus

Our pharmacist team will contact you within 2 hours to verify your prescription and insurance.

With Insurance

$0–$35/mo for most insured patients

Amgen SupportPlus

Uninsured / PAP

Free

Income-based assistance

Start My Order → 💬 WhatsApp 📞 Call

Avsola Overview

PropertyDetails
Brand NameAvsola
Generic Nameinfliximab-axxq
Reference BiologicRemicade (infliximab)
ManufacturerAmgen
Drug ClassTNF-alpha Inhibitor Biosimilar (IV)
FDA Approval2019
RouteIV infusion
Approved ConditionsRheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Plaque Psoriasis, Crohn's Disease, Ulcerative Colitis
Copay ProgramAmgen SupportPlus — $0–$35/mo for most insured patients

Approved Conditions

Rheumatoid ArthritisAnkylosing SpondylitisPsoriatic ArthritisPlaque PsoriasisCrohn's DiseaseUlcerative Colitis

Avsola vs Remicade (infliximab)

Avsola has been demonstrated to be biosimilar to Remicade (infliximab) through comprehensive analytical, non-clinical, and clinical studies. The FDA requires that biosimilars have no clinically meaningful differences from the reference product. Patients who are stable on Remicade (infliximab) should discuss any potential switch to Avsola with their prescriber.

FactorAvsolaRemicade (infliximab)
FDA StatusBiosimilar (approved 2019)Reference biologic
Active Ingredientinfliximab-axxqinfliximab
MechanismTNF-alpha Inhibitor)Same
Approved IndicationsSame as Remicade (infliximab)Multiple FDA-approved
Typical Patient Cost$0–$35/mo for most insured patients$0–$35/mo (varies by plan)
Yes. The FDA requires biosimilars to demonstrate there are no clinically meaningful differences in safety, purity, and potency compared to the reference product. Avsola underwent rigorous clinical studies demonstrating biosimilarity to Remicade (infliximab). Your prescriber can discuss whether Avsola is appropriate for your specific situation.
Many patients do switch from reference biologics to biosimilars. The decision should be made in consultation with your prescriber. Switching is generally safe for stable patients, but your doctor may want to monitor you during the transition. BiologicHealthPlus can coordinate the prior authorization for Avsola and ensure a seamless supply transition.
Most commercial insurance plans and Medicare Part D cover Avsola with prior authorization. In many cases, Avsola may have a lower tier placement on formularies than Remicade (infliximab), potentially reducing your copay. BiologicHealthPlus verifies your insurance coverage, handles all prior authorization, and enrolls you in the Amgen SupportPlus copay program to minimize your out-of-pocket costs.
Without insurance, Avsola costs approximately $4800/month at list price — lower than Remicade (infliximab)'s list price. Uninsured or underinsured patients may qualify for patient assistance through Amgen SupportPlus. BiologicHealthPlus will find every available savings option for you at no charge.

📚 Sources & Further Reading

🔗
FDA Biosimilar ApprovalsFDA
🔗
BiosimilarWikipedia
🔗
ACR Biosimilar PositionACR
🔗
Biosimilar DevelopmentNIH/NCBI
🔗
Medicare Biosimilar CoverageCMS

Medical Disclaimer: Educational content reviewed by BiologicHealthPlus Clinical Team. Last reviewed: August 2026.

Medical Disclaimer: This page is for informational purposes only. Avsola requires a valid prescription. Consult your physician before making any changes to your medication. Last updated: August 2026.